Sacituzumab Govitecan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and DMC (Denmark), among others, recommended or restricted sacituzumab govitecan, while NYE METODER (Norway) did not recommend it.
The record spans 4.7 years, opening at PBAC (Australia) in 2021 and running to 9 Mar 2026.
CIPM (Spain) changed its position: not recommended on 7 Jul 2022, recommended by 26 Sep 2024, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for sacituzumab govitecan, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 19 of 31 records date from 2023 or later.
7 distinct indication wordings are recorded for sacituzumab govitecan by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 31 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess sacituzumab govitecan, in 2021; PHARMAC (New Zealand) did not open a file until 29 Aug 2025 — a wide spread of 4.1 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 6 years in total.
11 of the 15 agencies here assessed sacituzumab govitecan more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
sacituzumab govitecan has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for sacituzumab govitecan reads 14 recommended, 9 not recommended, 2 restricted and 1 non-submission, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 29 Aug 2025 | Breast Cancer, Triple-Negative,Locally Advanced or Metastatic | PTAC advice: High | source |
| NICE (England) | 13 Aug 2025 | NICE TA1089 | terminated appraisal | source |
| AOTMIT (Poland) | 25 Jul 2025 | programu lekowego B.9.FM. „Leczenie chorych na raka piersi (ICD-10: C50) | recommended conditionally | source |
| DMC (Denmark) | 21 May 2025 | Metastatisk triple-negativ brystkræft | Anbefalet | source |
| AIFA (Italy) | 4 Mar 2025 | Trodelvy® in monoterapia è indicato per il trattamento di pazienti adulti con cancro della mammella positivo per i recet… | fully innovative · reimbursed class H | source |
26 further decisions for sacituzumab govitecan, across 13 agencies, are not shown here. They include the most recent record on file, 9 Mar 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 22 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 31 decisions for sacituzumab govitecan from 15 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.